Startups channel feed – Endpoints News

Startups channel feed

With 30-year industry chops, Pamela Conley launches a protein therapeutics biotech for autoimmune diseases

4 years ago

Working like a machine during the pandemic, MOMA taps investors to bankroll its 'molecular machines'

4 years ago

Scoop: ExeVir hits pause on llama-derived Covid antibody amid Omicron variants, shifts focus to second-gen work

4 years ago

Exclusive: Aspen Neuroscience collects large Series B to compete against Bayer's Parkinson's cell therapy

4 years ago

DCT startup looking to forge better community relationships nets a modest Series B

4 years ago

How do you pack 20 years of ADC learnings into one company? Tubulis has $63M more to answer that

4 years ago

After 45 investments in two years, Catalio reels in more funds to back 30 additional companies

4 years ago

5AM, Avidity, Fidelity lead $100M infusion into next-gen, targeted complement approach

4 years ago

James Boylan snags $300M to hunt for biotech deals after leaving SVB

4 years ago

University of Oxford spinoff nets a nine-figure Series B, but it won't beeline toward the clinic

4 years ago

Exclusive: Centrexion's knee pain drug fails two PhIII studies, but ex-Pfizer CEO Kindler's biotech might still ask for FDA nod

4 years ago

Syncona-backed biotech launches in bid to shield heart cells from heart attacks

4 years ago

Gene therapy outfit emerges from stealth with big ambitions. First stop — CAR-T

4 years ago

Caladrius’ 16-year rocky history bends again in Cend merger; After Cellectis, China JV pacts, Cytovia inks SPAC deal

4 years ago

Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target new 'don't eat me' signal

4 years ago

Deerfield-backed biotech emerges from stealth with gene therapy delivery platforms from Harvard and MIT

4 years ago

'Results are unambiguous': Eliem's lead program fails and share price halves before opening bell

4 years ago

Sandrock’s first month at Voyager sours as shares crumble on Levin, Paul’s move to step off the board

4 years ago

Welcome to 'tissue therapeutics’: Dave Lennon’s $110M new venture will implant ‘happy cells’ that ‘survive and thrive’

4 years ago

Flagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editing

4 years ago

'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market

4 years ago

Exclusive: En route to first xenotransplantation trial, eGenesis taps new CEO weeks after CMO hire

4 years ago

ARCH leads $130M infusion into Be Bio's long pursuit of B cell therapies for rare disease, cancer

4 years ago

AbbVie president Michael Severino heads to Flagship as biotech incubator's third CEO-partner in six days

4 years ago

First page Previous page 40 41 424344 45 46 Next page Last page